Researchers call for ‘evidence-based’ driving restrictions for patients treated with CAR-T therapy

Driving restrictions for blood cancer patients undergoing chimeric antigen receptor (CAR)-T cell therapy may need reconsideration.

Daratumumab monotherapy superior to active monitoring in high-risk smoldering myeloma

Daratumumab demonstrated a clinically meaningful and significant benefit compared with active monitoring, the current standard of care, for patients with high-risk smoldering multiple myeloma (SMM), according to results from the […]

Triplet regimen shows promise in relapsed or refractory multiple myeloma

Elranatamab in combination with carfilzomib and dexamethasone demonstrated clinical efficacy and predictable safety signals, according to the investigators of a phase 1b MagnetisMM-20 trial in relapsed or refractory multiple myeloma. […]